Cargando…

Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies

OBJECTIVE: Previous analyses of pooled DISCOVER‐1 and DISCOVER‐2 data through Week 24 showed significantly higher rates of dactylitis resolution in patients treated with guselkumab compared with placebo. Here, we investigate associations between dactylitis resolution and other outcomes through 1 yea...

Descripción completa

Detalles Bibliográficos
Autores principales:	McGonagle, Dennis, McInnes, Iain B., Deodhar, Atul, Schett, Georg, Shawi, May, Chakravarty, Soumya D., Kollmeier, Alexa P., Xu, Xie L., Sheng, Shihong, Xu, Stephen, Ritchlin, Christopher T., Rahman, Proton, Mease, Phillip J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100698/ https://www.ncbi.nlm.nih.gov/pubmed/36880890 http://dx.doi.org/10.1002/acr2.11537

Ejemplares similares

Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies
por: McGonagle, Dennis, et al.
Publicado: (2021)

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
por: Ritchlin, Christopher T, et al.
Publicado: (2022)

Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis
por: Gottlieb, Alice B, et al.
Publicado: (2023)

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
por: Mease, Philip J., et al.
Publicado: (2023)

Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis
por: McInnes, Iain B., et al.
Publicado: (2022)

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study
por: Mease, Philip J, et al.
Publicado: (2020)

Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis
por: McInnes, Iain B., et al.
Publicado: (2021)

Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis
por: Mease, Philip J, et al.
Publicado: (2022)

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial
por: Ritchlin, Christopher T., et al.
Publicado: (2023)

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
por: Mease, Philip J, et al.
Publicado: (2021)

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study
por: Ritchlin, Christopher T., et al.
Publicado: (2023)

Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis
por: Rahman, Proton, et al.
Publicado: (2021)

Psoriatic Dactylitis: Current Perspectives and New Insights in Ultrasonography and Magnetic Resonance Imaging
por: Girolimetto, Nicolò, et al.
Publicado: (2021)

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced
por: Ritchlin, Christopher T, et al.
Publicado: (2021)

Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study
por: Orbai, Ana-Maria, et al.
Publicado: (2022)

High-resolution MRI assessment of dactylitis in psoriatic arthritis shows flexor tendon pulley and sheath-related enthesitis
por: Tan, Ai Lyn, et al.
Publicado: (2015)

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
por: Orbai, Ana-Maria, et al.
Publicado: (2023)

Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)
por: Schett, Georg, et al.
Publicado: (2022)

Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with psoriatic arthritis
por: Chen, Yang, et al.
Publicado: (2021)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
por: Coates, Laura C, et al.
Publicado: (2022)

Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2022)

Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study
por: Schett, Georg, et al.
Publicado: (2023)

Publisher Correction to: Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)
por: Schett, Georg, et al.
Publicado: (2022)

Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
por: Gladman, Dafna D., et al.
Publicado: (2022)

Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study
por: Schett, Georg, et al.
Publicado: (2023)

Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo‐Controlled Trials
por: Siebert, Stefan, et al.
Publicado: (2023)

The Impact of Intermittent Fasting (Ramadan Fasting) on Psoriatic Arthritis Disease Activity, Enthesitis, and Dactylitis: A Multicentre Study
por: Adawi, Mohammad, et al.
Publicado: (2019)

Arthritis Interception in Patients with Psoriasis Treated with Guselkumab
por: Zabotti, Alen, et al.
Publicado: (2021)

The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
por: McGonagle, Dennis G, et al.
Publicado: (2019)

Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial
por: Helliwell, Philip S., et al.
Publicado: (2020)

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
por: Coates, Laura C., et al.
Publicado: (2019)

Optimal management of dactylitis in patients with psoriatic arthritis
por: Yamamoto, Toshiyuki
Publicado: (2015)

Corticosteroid injection treatment for dactylitis in psoriatic arthritis
por: Carriero, Antonio, et al.
Publicado: (2021)

Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes
por: McInnes, Iain B, et al.
Publicado: (2022)

Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
por: Mease, Philip, et al.
Publicado: (2016)

Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis
por: Dubash, Sayam, et al.
Publicado: (2022)

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies
por: Gladman, Dafna D, et al.
Publicado: (2018)

Guselkumab: widened action in psoriatic disease
por: Arnone, Marcelo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qt39k1gg2mv0v05s05dltmolvj